{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:25Z","timestamp":1791245185110,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004503","name":"Benha University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004503","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiotoxicity is a recognized adverse effect associated with anti-HER2 therapies. The Trastuzumab-mediated cardiac dysfunction is not dose-dependent and lacks ultrastructural changes, allowing potential recovery after a few months. There is no consensus on the management of patients who develop cardiotoxicity. This meta-analysis aims to assess the safety of the permissive cardiotoxicity of Trastuzumab in patients with breast cancer. We searched PubMed, Cochrane Library, and Embase up to October 2023 for retrospective or prospective studies that investigated the safety of Trastuzumab in patients with breast cancer who continued Trastuzumab therapy after asymptomatic ejection fraction (EF) decline. We conducted a pooled meta-analysis for the subsequent cardiac events, cardiac mortality, and all-cause mortality. We assessed the quality of included studies using the Newcastle\u2013Ottawa Scale and ROBIN-1 tool. A total of eight cohort studies (six retrospective and two prospective), comprising 222 patients, were found eligible and were included in our analysis. The pooled incidence of cardiac events, cardiac-related mortality, and all-cause mortality was 18% (95% CI 13% to 24%), 5% (95% CI 2% to 10%), and 8% (95% CI 2% to 28%), respectively. The incidence of symptomatic or severe cardiac events was lower in those who received cardioprotective medications concomitant with Trastuzumab. Most patients received either angiotensin-converting-enzyme inhibitors, beta-blockers, or a combination of both. Continuation of planned Trastuzumab therapy with concomitant use of cardioprotective medications can be a safe and effective approach for breast\u00a0cancer\u00a0control in patients with asymptomatic EF decline.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s12012-025-10037-z","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T23:03:27Z","timestamp":1751929407000},"page":"1369-1380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety of Permissive Cardiotoxicity of Trastuzumab in Patients with Breast Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"25","author":[{"given":"Amira Mohamed","family":"Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez M.","family":"Odat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesam Abd El-Tawab","family":"Moawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Adel Abdelkader","family":"Saed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7787-5508","authenticated-orcid":false,"given":"Basma Ehab","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dang","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalal Salama","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loay","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"10037_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10037_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87\u2013108. https:\/\/doi.org\/10.3322\/caac.21262","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10037_CR3","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C., Somerfield, M. R., Dowsett, M., Hammond, M. E. H., Hayes, D. F., Mcshane, L. M., Saphner, T. J., Spears, P. A., & Allison, K. H. (2023). Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American pathologists guideline update. Journal of Clinical Oncology, 41, 3867\u20133872. https:\/\/doi.org\/10.1200\/JCO.22.02864","journal-title":"Journal of Clinical Oncology"},{"key":"10037_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1634\/theoncologist.2018-0213","volume":"24","author":"Y Wong","year":"2019","unstructured":"Wong, Y., Raghavendra, A. S., Hatzis, C., Irizarry, J. P., Vega, T., Horowitz, N., Barcenas, C. H., Chavez-MacGregor, M., Valero, V., Tripathy, D., Pusztai, L., & Murthy, R. K. (2019). Long-Term survival of de novo stage IV human epidermal growth receptor 2 (HER2) positive breast cancers treated with HER2-targeted therapy. The Oncologist, 24, 313\u2013318. https:\/\/doi.org\/10.1634\/theoncologist.2018-0213","journal-title":"The Oncologist"},{"key":"10037_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10549-017-4489-9","volume":"167","author":"N Niikura","year":"2018","unstructured":"Niikura, N., Shimomura, A., Fukatsu, Y., Sawaki, M., Ogiya, R., Yasojima, H., Fujisawa, T., Yamamoto, M., Tsuneizumi, M., Kitani, A., Watanabe, J., Matsui, A., Takahashi, Y., Takashima, S., Shien, T., Tamura, K., Saji, S., Masuda, N., Tokuda, Y., & Iwata, H. (2018). Durable complete response in HER2-positive breast cancer: A multicenter retrospective analysis. Breast Cancer Research and Treatment, 167, 81\u201387. https:\/\/doi.org\/10.1007\/s10549-017-4489-9","journal-title":"Breast Cancer Research and Treatment"},{"key":"10037_CR6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/annonc\/mdt543","volume":"25","author":"J Baselga","year":"2014","unstructured":"Baselga, J., Manikhas, A., Cort\u00e9s, J., Llombart, A., Roman, L., Semiglazov, V. F., Byakhov, M., Lokanatha, D., Forenza, S., Goldfarb, R. H., Matera, J., Azarnia, N., Hudis, C. A., & Rozencweig, M. (2014). Phase III trial of nonpegylated liposomal doxorubicin in combination with Trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Annals of Oncology, 25, 592\u2013598. https:\/\/doi.org\/10.1093\/annonc\/mdt543","journal-title":"Annals of Oncology"},{"key":"10037_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006243.pub2","author":"L Moja","year":"2012","unstructured":"Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., & D\u2019Amico, R. (2012). Trastuzumab containing regimens for early breast cancer. Cochrane Database Systematic Reviews. https:\/\/doi.org\/10.1002\/14651858.CD006243.pub2","journal-title":"Cochrane Database Systematic Reviews"},{"key":"10037_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1200\/JCO.2004.01.120","volume":"22","author":"EA Perez","year":"2004","unstructured":"Perez, E. A., & Rodeheffer, R. (2004). Clinical cardiac tolerability of Trastuzumab. Journal of Clinical Oncology, 22, 322\u2013329. https:\/\/doi.org\/10.1200\/JCO.2004.01.120","journal-title":"Journal of Clinical Oncology"},{"key":"10037_CR9","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/cncr.10854","volume":"95","author":"DL Keefe","year":"2002","unstructured":"Keefe, D. L. (2002). Trastuzumab-associated cardiotoxicity. Cancer, 95, 1592\u20131600. https:\/\/doi.org\/10.1002\/cncr.10854","journal-title":"Cancer"},{"key":"10037_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10549-020-06039-w","volume":"186","author":"NI Bouwer","year":"2021","unstructured":"Bouwer, N. I., Steenbruggen, T. G., van Rosmalen, J., Rier, H. N., Kitzen, J. J. E. M., van Bekkum, M. L., Tije, A. J. T., de Jong, P. C., Drooger, J. C., Holterhues, C., Smorenburg, C. H., Kofflard, M. J. M., Boersma, E., Sonke, G. S., Levin, M. D., & Jager, A. (2021). Cardiotoxicity during long-term Trastuzumab use in patients with HER2-positive metastatic breast cancer: Who needs cardiac monitoring? Breast Cancer Research and Treatment, 186, 851\u2013862. https:\/\/doi.org\/10.1007\/s10549-020-06039-w","journal-title":"Breast Cancer Research and Treatment"},{"key":"10037_CR11","doi-asserted-by":"publisher","first-page":"E712","DOI":"10.1093\/oncolo\/oyad086","volume":"28","author":"S Zhou","year":"2023","unstructured":"Zhou, S., Cirne, F., Chow, J., Zereshkian, A., Bordeleau, L., Dhesy-Thind, S., Ellis, P. M., Mukherjee, S. D., Aghel, N., & Leong, D. P. (2023). Three-Year outcomes following permissive cardiotoxicity in patients on Trastuzumab. The Oncologist, 28, E712\u2013E722. https:\/\/doi.org\/10.1093\/oncolo\/oyad086","journal-title":"The Oncologist"},{"key":"10037_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","volume":"4","author":"C Porter","year":"2022","unstructured":"Porter, C., Azam, T. U., Mohananey, D., Kumar, R., Chu, J., Lenihan, D., Dent, S., Ganatra, S., Beasley, G. S., & Okwuosa, T. (2022). Permissive cardiotoxicity: The clinical crucible of cardio-oncology. JACC CardioOncology, 4, 302\u2013312. https:\/\/doi.org\/10.1016\/j.jaccao.2022.07.005","journal-title":"JACC CardioOncology"},{"key":"10037_CR13","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/14740338.2022.2151584","volume":"21","author":"P Di Nardo","year":"2022","unstructured":"Di Nardo, P., Lisanti, C., Garutti, M., Buriolla, S., Alberti, M., Mazzeo, R., & Puglisi, F. (2022). Chemotherapy in patients with early breast cancer: Clinical overview and management of long-term side effects. Expert Opinion on Drug Safety, 21, 1341\u20131355. https:\/\/doi.org\/10.1080\/14740338.2022.2151584","journal-title":"Expert Opinion on Drug Safety"},{"key":"10037_CR14","doi-asserted-by":"publisher","unstructured":"Hudis CA, Martino S, Gralow JR, Dakhil SR (2014) NIH Public Access. 26:1231\u20131238. https:\/\/doi.org\/10.1200\/JCO.2007.13.5467.Cardiac","DOI":"10.1200\/JCO.2007.13.5467.Cardiac"},{"key":"10037_CR15","doi-asserted-by":"publisher","unstructured":"Azambuja E De, Procter MJ, Veldhuisen DJ Van, Agbor-tarh D, Metzger-filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-jones B, Dowsett M, Gelber RD, Piccart-gebhart MJ, Suter TM (2014) Trastuzumab-Associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial ( BIG. 1\u20139. https:\/\/doi.org\/10.1200\/JCO.2013.53.9288","DOI":"10.1200\/JCO.2013.53.9288"},{"key":"10037_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-007-9663-z","volume":"109","author":"E Bria","year":"2008","unstructured":"Bria, E., Cuppone, \u00c6. F., Fornier, \u00c6. M., Carlini, \u00c6. P., & Milella, \u00c6. M. (2008). Cardiotoxicity and incidence of brain metastases after adjuvant Trastuzumab for early breast cancer: The dark side of the moon\u202f? A meta-analysis of the randomized trials. Breast Cancer Research and Treatment, 109, 231\u2013239. https:\/\/doi.org\/10.1007\/s10549-007-9663-z","journal-title":"Breast Cancer Research and Treatment"},{"issue":"11","key":"10037_CR17","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2021","unstructured":"Lyon, A. R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., & Lenihan, D. (2021). Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the cardio- oncology study group of the heart failure association of the European society. European Journal of Heart Failure, 22(11), 1945\u20131960. https:\/\/doi.org\/10.1002\/ejhf.1920","journal-title":"European Journal of Heart Failure"},{"key":"10037_CR18","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T PM (2022) Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane"},{"key":"10037_CR19","doi-asserted-by":"publisher","unstructured":"Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann C, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-wilson E, Mcdonald S, Mcguinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement\u202f: An updated guideline for reporting systematic reviews Systematic reviews and Meta-Analyses. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"10037_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang, A. (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology, 25, 603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"European Journal of Epidemiology"},{"key":"10037_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","author":"JAC Sterne","year":"2016","unstructured":"Sterne, J. A. C., Hern\u00e1n, M. A., Reeves, B. C., Savovi\u0107, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., Carpenter, J. R., Chan, A., Churchill, R., Deeks, J. J., Hr\u00f3bjartsson, A., Kirkham, J., J\u00fcni, P., Loke, Y. K., Pigott, T. D., \u2026 Higgins, J. P. T. (2016). ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions (\u201c Risk of bias in non-randomised tool for evaluating risk of bias in. BMJ. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"10037_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal, 315, 629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"British Medical Journal"},{"key":"10037_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., R\u00fccker, G., Harbord, R. M., Schmid, C. H., Tetzlaff, J., Deeks, J. J., Peters, J., Macaskill, P., Schwarzer, G., Duval, S., Altman, D. G., Moher, D., & Higgins, J. P. T. (2011). Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ, 343, 1\u20138. https:\/\/doi.org\/10.1136\/bmj.d4002","journal-title":"BMJ"},{"key":"10037_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008637","author":"S Nowsheen","year":"2018","unstructured":"Nowsheen, S., Aziz, K., Park, J. Y., Lerman, A., Villarraga, H. R., Ruddy, K. J., & Herrmann, J. (2018). Trastuzumab in female breast cancer patients with reduced left ventricular ejection fraction. Journal of American Heart Association. https:\/\/doi.org\/10.1161\/JAHA.118.008637","journal-title":"Journal of American Heart Association"},{"issue":"4","key":"10037_CR25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3747\/co.26.4631","volume":"26","author":"CC Barron","year":"2019","unstructured":"Barron, C. C., Alhussein, M. M., Kaur, U., Cosman, T. L., Tyagi, N. K., Brown, M., Mukherjee, S. D., Ellis, P. M., Dhesy-Thind, S., & Leong, D. P. (2019). An evaluation of the safety of continuing Trastuzumab despite overt left ventricular dysfunction. Current Oncology, 26(4), 240\u2013246.","journal-title":"Current Oncology"},{"key":"10037_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s10549-019-05139-6","volume":"175","author":"Y Hussain","year":"2019","unstructured":"Hussain, Y., Drill, E., Dang, C. T., Liu, J. E., Steingart, R. M., & Yu, A. F. (2019). Cardiac outcomes of Trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction. Breast Cancer Research and Treatment, 175, 239\u2013246. https:\/\/doi.org\/10.1007\/s10549-019-05139-6","journal-title":"Breast Cancer Research and Treatment"},{"key":"10037_CR27","doi-asserted-by":"publisher","unstructured":"(2019) Safety of continuing Trastuzumab. 1: 1\u201310. https:\/\/doi.org\/10.1016\/j.jaccao.2019.06.004","DOI":"10.1016\/j.jaccao.2019.06.004"},{"key":"10037_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","volume":"175","author":"FLA Barac","year":"2019","unstructured":"Barac, F. L. A., Dang, X. G. C., Yu, A. F., Smith, K. L., & Nunes, C. G. P. R. P. R. (2019). Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: The SAFE-HEaRt study. Breast Cancer Research and Treatment, 175, 595\u2013603. https:\/\/doi.org\/10.1007\/s10549-019-05191-2","journal-title":"Breast Cancer Research and Treatment"},{"key":"10037_CR29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-020-06053-y","volume":"185","author":"K Khoury","year":"2021","unstructured":"Khoury, K., Lynce, F., Barac, A., Geng, X., Dang, C., Yu, A. F., Smith, K. L., Gallagher, C., Pohlmann, P. R., Nunes, R., Herbolsheimer, P., Warren, R., Srichai, M. B., Hofmeyer, M., Asch, F., Tan, M., Isaacs, C., & Swain, S. M. (2021). Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Research and Treatment, 185, 863\u2013868. https:\/\/doi.org\/10.1007\/s10549-020-06053-y","journal-title":"Breast Cancer Research and Treatment"},{"issue":"4","key":"10037_CR30","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ijc.34024","volume":"151","author":"NI Bouwer","year":"2022","unstructured":"Bouwer, N. I., Steenbruggen, T. G., Rier, H. N., Kitzen, J. J., Smorenburg, C. H., van Bekkum, M. L., de Jong, P. C., Drooger, J. C., Holterhues, C., Kofflard, M. J., & Boersma, E. (2022). The effect of Trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction. International Journal of Cancer, 151(4), 616\u2013622. https:\/\/doi.org\/10.1002\/ijc.34024","journal-title":"International Journal of Cancer"},{"issue":"21","key":"10037_CR31","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.3390\/jcm12216708","volume":"12","author":"O de la Brassinne Bonardeaux","year":"2023","unstructured":"de la Brassinne Bonardeaux, O., Born, B., Moonen, M., & Lancellotti, P. (2023). Mild cardiotoxicity and continued Trastuzumab treatment in the context of HER2-Positive breast cancer. Journal of Clinical Medicine, 12(21), 6708.","journal-title":"Journal of Clinical Medicine"},{"key":"10037_CR32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa053028","volume":"354","author":"R Kokko","year":"2006","unstructured":"Kokko, R., Hemminki, A., Tarkkanen, M., J\u00e4\u00e4skel\u00e4inen, A., Pajunen, M., & Rauhala, M. (2006). Adjuvant docetaxel or Vinorelbine with or without Trastuzumab for breast cancer. New England Journal of Medicine, 354, 809\u2013820.","journal-title":"New England Journal of Medicine"},{"key":"10037_CR33","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"VJ Suman","year":"2005","unstructured":"Suman, V. J., Ph, D., Geyer, C. E., Davidson, N. E., Tan-chiu, E., Martino, S., Paik, S., Kaufman, P. A., Swain, S. M., Pisansky, T. M., Fehrenbacher, L., Kutteh, L. A., Vogel, V. G., Visscher, D. W., Yothers, G., Ph, D., Jenkins, R. B., Ph, D., Brown, A. M., \u2026 Dakhil, S. R. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-Positive breast cancer. New England Journal of Medicine, 353, 1673\u20131684.","journal-title":"New England Journal of Medicine"},{"key":"10037_CR34","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"M Untch","year":"2005","unstructured":"Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, D., Dowsett, M., Ph, D., Barrios, C. H., Steger, G., Lohrisch, C., Suter, T. M., R\u00fcschoff, J., & S\u00fcto, T. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal, 353, 1659\u20131672.","journal-title":"New England Journal"},{"key":"10037_CR35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1253\/circj.CJ-24-0065","volume":"88","author":"K Inoue","year":"2024","unstructured":"Inoue, K., Machino-Ohtsuka, T., Nakazawa, Y., Iida, N., Sasamura, R., Bando, H., Chiba, S., Tasaka, N., Ishizu, T., Murakoshi, N., Xu, D., Sekine, I., & Tajiri, K. (2024). Early detection and prediction of anthracycline-induced cardiotoxicity - a prospective cohort study -. Circulation Journal, 88, 751\u2013759. https:\/\/doi.org\/10.1253\/circj.CJ-24-0065","journal-title":"Circulation Journal"},{"key":"10037_CR36","doi-asserted-by":"publisher","first-page":"350","DOI":"10.21037\/gs.2017.11.09","volume":"7","author":"JN Upshaw","year":"2018","unstructured":"Upshaw, J. N. (2018). Cardio-oncology: Protecting the heart from curative breast cancer treatment. Gland Surgery, 7, 350\u2013365. https:\/\/doi.org\/10.21037\/gs.2017.11.09","journal-title":"Gland Surgery"},{"issue":"4","key":"10037_CR37","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamacardio.2023.5692","volume":"9","author":"MJ LaMonte","year":"2024","unstructured":"LaMonte, M. J., LaCroix, A. Z., Nguyen, S., Evenson, K. R., Di, C., Stefanick, M. L., & Eaton, C. B. (2024). Accelerometer-Measured physical activity, sedentary time, and heart failure risk in women aged 63 to 99 years. JAMA Cardiology, 9(4), 336\u2013345. https:\/\/doi.org\/10.1001\/jamacardio.2023.5692","journal-title":"JAMA Cardiology"},{"key":"10037_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-020-00070-y","volume":"6","author":"E Hedayati","year":"2020","unstructured":"Hedayati, E., Papakonstantinou, A., M\u00e5nsson-Broberg, A., Bergh, J., Hubbert, L., & Altena, R. (2020). Approaches to management of cardiovascular morbidity in adult cancer patients - Cross-sectional survey among cardio-oncology experts. Cardio-Oncology, 6, 1\u201312. https:\/\/doi.org\/10.1186\/s40959-020-00070-y","journal-title":"Cardio-Oncology"},{"key":"10037_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/atm-20-4640","volume":"9","author":"C Espinoza","year":"2021","unstructured":"Espinoza, C., Alkhateeb, H., & Siddiqui, T. (2021). Updates in pharmacotherapy of heart failure with reduced ejection fraction. Annals of Translational Medicine, 9, 1\u201311. https:\/\/doi.org\/10.21037\/atm-20-4640","journal-title":"Annals of Translational Medicine"},{"key":"10037_CR40","doi-asserted-by":"publisher","unstructured":"Enzan N, Matsushima S, Ide T, Kaku H (2021) Blocker use is associated with prevention of left ventricular remodeling in. https:\/\/doi.org\/10.1161\/JAHA.120.019240","DOI":"10.1161\/JAHA.120.019240"},{"key":"10037_CR41","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1093\/eurheartj\/ehac270","volume":"43","author":"S Halvorsen","year":"2022","unstructured":"Halvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., Abdelhamid, M., Barbato, E., De Hert, S., De Laval, I., Geisler, T., Hinterbuchner, L., Ibanez, B., Lenarczyk, R., Mansmann, U. R., McGreavy, P., Mueller, C., Muneretto, C., Niessner, A., Potpara, T. S., Risti\u0107, A., \u2026 Zacharowski, K. (2022). 2022 ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. European Heart Journal, 43, 3826\u20133924. https:\/\/doi.org\/10.1093\/eurheartj\/ehac270","journal-title":"European Heart Journal"},{"key":"10037_CR42","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld, K., Tfelt-Hansen, J., De Riva, M., Winkel, B. G., Behr, E. R., Blom, N. A., (2022). 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal, 43, 3997\u20134126.","journal-title":"European Heart Journal"},{"issue":"5","key":"10037_CR43","doi-asserted-by":"publisher","first-page":"100723","DOI":"10.1016\/j.currproblcancer.2021.100723","volume":"45","author":"G Koulaouzidis","year":"2021","unstructured":"Koulaouzidis, G., Yung, A. E., Yung, D. E., Skonieczna-\u017bydecka, K., Marlicz, W., Koulaouzidis, A., & Charisopoulou, D. (2021). Conventional cardiac risk factors associated with Trastuzumab-induced cardiotoxicity in breast cancer: Systematic review and meta-analysis. Current Problems in Cancer, 45(5), 100723. https:\/\/doi.org\/10.1016\/j.currproblcancer.2021.100723","journal-title":"Current Problems in Cancer"},{"key":"10037_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0786-x","author":"D Eiger","year":"2020","unstructured":"Eiger, D., Pond\u00e9, N. F., Agbor-tarh, D., Moreno-aspitia, A., Piccart, M., Hilbers, F. S., Werner, O., Chumsri, S., Dueck, A., Kroep, J. R., Gomez, H., L\u00e1ng, I., & Rodeheffer, R. J. (2020). Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and \/ or Trastuzumab treatment optimization trial. British Journal of Cancer. https:\/\/doi.org\/10.1038\/s41416-020-0786-x","journal-title":"British Journal of Cancer"},{"key":"10037_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-021-00099-7","volume":"7","author":"RJR Yao","year":"2021","unstructured":"Yao, R. J. R., Gibson, J., Simmons, C., & Davis, M. K. (2021). Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during Trastuzumab therapy. Cardio-Oncology, 7, 1\u201312.","journal-title":"Cardio-Oncology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10037-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-025-10037-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-025-10037-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:24:30Z","timestamp":1757208270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-025-10037-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10037"],"URL":"https:\/\/doi.org\/10.1007\/s12012-025-10037-z","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study formal consent is not required. This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}